✦ LIBER ✦

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

✍ Scribed by Paul M Ridker; Jacques Genest; S Matthijs Boekholdt; Peter Libby; Antonio M Gotto; Børge G Nordestgaard; Samia Mora; Jean G MacFadyen; Robert J Glynn; John JP Kastelein

Book ID: 117306699
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 144 KB
Volume: 376
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)60713-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiovascular benefits and diabetes ris

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

✍ Paul M Ridker; Aruna Pradhan; Jean G MacFadyen; Peter Libby; Robert J Glynn 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 322 KB

Cardiovascular Benefits and Diabetes Ris

Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis From the JUPITER Trial

✍ Ridker, P.M.; Pradhan, A.; MacFadyen, J.G. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 72 KB

On-Treatment Non–High-Density Lipoprotei

On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)

✍ Samia Mora; Robert J. Glynn; S. Matthijs Boekholdt; Børge G. Nordestgaard; John 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 273 KB

HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTER

HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL IS ASSOCIATED WITH RESIDUAL RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE DESPITE OPTIMAL LEVELS OF LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL: A POST HOC ANALYSIS FROM THE COURAGE TRIAL

✍ Acharjee, Subroto; Boden, William E.; Hartigan, Pamela M.; Teo, Koon K.; Maron, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Relationship of Lipoprotein-Associated P

Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial

✍ Ridker, P. M.; MacFadyen, J. G.; Wolfert, R. L.; Koenig, W. 📂 Article 📅 2012 🏛 American Association for Clinical Chemistry 🌐 English ⚖ 229 KB